Introduction
============

Liver cancer is a common malignant tumor type with high morbidity and mortality ([@b1-etm-0-0-8726]). Although various treatments have been improved, the mortality rate of liver cancer is still high and the prognosis remains poor ([@b2-etm-0-0-8726],[@b3-etm-0-0-8726]). Therefore, prognostic biomarkers of liver cancer have become one of the hotspots of current research ([@b4-etm-0-0-8726]). The discovery of accurate prognostic biomarkers may contribute to clinical guidance in order to improve the evaluation system of liver cancer.

The family of eukaryotic translation initiation factors (EIFs) participates in eukaryotic translation by regulating the interaction between ribosomes and RNA. It is the rate-limiting step of protein synthesis and participates in numerous processes that are deregulated in cancer cells, including DNA repair and proliferation, cell cycle and apoptosis ([@b5-etm-0-0-8726]). EIF 3 subunit B (EIF3B) is an important member of the family of EIFs and has been observed to be overexpressed in numerous cancer types, including clear cell renal cell carcinoma ([@b6-etm-0-0-8726]), esophageal squamous cell carcinoma ([@b7-etm-0-0-8726]), glioblastoma ([@b8-etm-0-0-8726]), ovarian cancer ([@b9-etm-0-0-8726]), osteosarcoma ([@b10-etm-0-0-8726]) and lung cancer ([@b11-etm-0-0-8726]), and has an important role in the progression and prognosis of several cancer types ([@b12-etm-0-0-8726]). In addition, Golob-Schwarzl *et al* ([@b15-etm-0-0-8726]) reported that EIF3B was upregulated in hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCC). However, the precise role of EIF3B in liver cancer has remained elusive.

To further evaluate the roles of EIF3B in patients with liver cancer, the expression of EIF3B was examined in a dataset from The Cancer Genome Atlas (TCGA) database. The χ^2^ and Fisher\'s exact tests were used to assess the association of EIF3B with clinicopathological parameters and demographic features. Receiver operating characteristics (ROC) curve analysis was used for evaluating the diagnostic value of EIF3B. Kaplan-Meier overall survival and relapse-free survival analysis were performed to determine the association between EIF3B expression and survival. Univariate and multivariate Cox regression analysis were performed to identify the factors affecting overall survival and relapse-free survival. Furthermore, gene set enrichment analysis (GSEA) was used to explore EIF3B-associated signaling pathways.

Materials and methods
=====================

### Data source

The clinical information of patients and their RNAseq data were obtained from TCGA (<https://cancergenome.nih.gov/>). All patients from the liver hepatocellular carcinoma (LIHC) cohort were screened based on TCGA inclusion and exclusion pre-selection criteria.

### Statistical analysis

R (version 3.6.1; The R Foundation) ([@b16-etm-0-0-8726]) was used for statistical analysis (t-test, Kruskal-Wallis with Dunn\'s post-hoc test, Wilcoxon sum-rank test) and generation of images. The ggplot2 package ([@b17-etm-0-0-8726]) was used to draw boxplots of the EIF3B expression in subgroups by clinical characteristics. χ^2^ and Fisher\'s exact tests were applied to estimate the significance of the association between EIF3B expression and clinicopathological or demographic characteristics. The pROC package ([@b18-etm-0-0-8726]) was used to plot the ROC curves and assess the diagnostic ability of EIF3B, and patients were divided into a high expression group and low expression group according to the best operating system cut-off value determined by the Youden index. The survival package ([@b19-etm-0-0-8726]) was used to draw survival curves. A univariate Cox linear regression model was utilized to select correlative variables affecting survival time. Multivariate Cox regression analysis was employed to evaluate the independent influencing factors of survival time.

### GSEA

GSEA may be used to determine whether a predefined set of genes is able to indicate significant, consistent differences between two biological states ([@b20-etm-0-0-8726]). In the present study, GSEA was performed in the 'h.all.v6.2.symbols.gmt' and 'c2. cp.biocarta.v6.2.symbols.gmt' gene sets using GSEA3.0 software. The standardized enrichment fraction was obtained by 1,000 permutation analyses.

Results
=======

### Patient characteristics

In [Table I](#tI-etm-0-0-8726){ref-type="table"}, the clinical features of the 373 patient cohort, including sex (female 121, male 252), age (16-90 years old, median 61, mean 59.47), use of radiation therapy, residual tumor, relapse-free survival, histological type, stage, vital status, survival data, T/N/M classification and EIF3B expression are provided.

### Expression of EIF3B in liver tissues

Boxplots revealed that EIF3B was significantly upregulated in liver cancer compared with that in normal liver tissues ([Fig. 1A](#f1-etm-0-0-8726){ref-type="fig"}; P\<0.001). Furthermore, EIF3B was also differentially expressed between subgroups by vital status (P=0.005) and histologic grade (P\<0.001; [Fig. 1](#f1-etm-0-0-8726){ref-type="fig"}).

### Diagnostic capability of EIF3B

To assess the diagnostic performance of EIF3B in liver cancer, ROC curve analysis was used. The area under the curve (AUC) was 0.821, indicating that EIF3B has moderate diagnostic ability. In addition, similar AUCs were obtained for distinguishing normal liver tissues from liver cancer at specific stages (stage I, 0.785; stage II, 0.850; stage III, 0.853; stage IV, 0.916; [Fig. 2](#f2-etm-0-0-8726){ref-type="fig"}).

### Association between EIF3B expression and clinical features of patients with liver cancer

As indicated in [Table II](#tII-etm-0-0-8726){ref-type="table"}, the vital status of the patients with liver cancer (P\<0.001), overall survival (P\<0.001; duration ten years) and the histologic grade (P\<0.001) were associated with the expression of EIF3B.

### High expression of EIF3B is associated with poor overall survival of patients with liver cancer

Kaplan-Meier analysis indicated that high expression of EIF3B was significantly associated with poor overall survival (P\<0.001; [Fig. 3](#f3-etm-0-0-8726){ref-type="fig"}). Subgroup analysis provided similar results, particularly in female (P\<0.001), younger (\<55; P=0.008) and older subjects (≥55; P\<0.001), and in patients with R0 (P\<0.001), G2 (P=0.003), G3 (P\<0.0001), stage I (P\<0.001) and stage III (P\<0.001).

As presented in [Table III](#tIII-etm-0-0-8726){ref-type="table"}, T classification, stage, residual tumor and EIF3B expression were variables associated with overall survival according to univariate Cox regression analysis. In addition, multivariate Cox regression indicated that high EIF3B expression, T classification and residual tumor were independent risk factors for overall survival of patients with liver cancer \[hazard ratio (HR)=2.44, 95% CI=1.71-3.47, P\<0.001\].

### High expression of EIF3B is associated with poor relapse-free survival of patients with liver cancer

Kaplan-Meier analysis indicated that patients with high expression of EIF3B had significantly poorer relapse-free survival (P=0.013; [Fig. 4](#f4-etm-0-0-8726){ref-type="fig"}). Subgroup analysis provided similar results, particularly in female (P=0.001) and older (≥55; P=0.032) subjects and in patients with R0 (P=0.020), G2 (P\<0.001) and stage III (P=0.004).

As presented in [Table IV](#tIV-etm-0-0-8726){ref-type="table"}, T classification, stage, residual tumor and EIF3B expression were variables associated with relapse-free survival according to the univariate Cox regression analysis. In addition, high EIF3B expression, T classification and residual tumor were independent risk factors for relapse-free survival of patients with liver cancer in the multivariate Cox regression analysis (HR=1.54, 95% CI=1.06-2.23, P=0.022).

### Signaling pathways associated with EIF3B

To identify the signaling pathways associated with EIF3B in liver cancer, GSEA was performed between the low EIF3B expression dataset and the high EIF3B expression dataset. The enrichment of the molecular signatures database (MSigDB) determined by GSEA was significantly different (nominal P-value \<0.050, false discovery rate \<0.250; [Table V](#tV-etm-0-0-8726){ref-type="table"}). As presented in [Fig. 5](#f5-etm-0-0-8726){ref-type="fig"} and [Table V](#tV-etm-0-0-8726){ref-type="table"}, GSEA indicated that MYC-V1 (HALLMARK_MYC_TARGETS_V1 geneset; P=0.009), MYC-V2 (HALLMARK_MYC_TARGETS_V2 geneset; P=0.004) and DNA repair pathways (HALLMARK_DNA_REPAIR geneset; P\<0.001) were differentially enriched in high EIF3B expression and low EIF3B expression groups.

Discussion
==========

Liver cancer is associated with a high mortality rate worldwide; the development of this cancer type may be influenced by viral infection, diet and environmental factors ([@b21-etm-0-0-8726]). In recent years, with the continuous progression of molecular biology and treatments, including chemotherapeutic drugs and surgical technology, the understanding of cancer biology and the treatment of liver cancer have made great progress. However, the prognosis of liver cancer remains poor. The World Health Organization/International Classification of Diseases-10 classifies diseases according to their etiology, pathology, clinical manifestations and anatomical location. Cancer is a gene-associated disease and molecular typing is required to deepen our understanding of the underlying mechanisms of disease development ([@b25-etm-0-0-8726]). Therefore, novel biomarkers are urgently required. Our research group has been exploring novel biomarkers for a number of years ([@b26-etm-0-0-8726]). The present study focused on EIF3B and indicated that EIF3B is a potential and independent prognostic biomarker for liver cancer.

EIF3B is closely linked to cancer progression. Consistent with previous studies, it was indicated that EIF3B was highly expressed in patients with liver cancer. Although Golob-Schwarzl *et al* ([@b15-etm-0-0-8726]) reported that EIF3B was upregulated in HCV-associated HCC, all of their patients were Asians. The patients assessed in the present study were from all over the world and covered other types of liver cancer that may be related to HCV. All of these results indicate that EIF3B has an important role in cancer-associated processes. A previous study suggested that EIF3B is involved in the proliferation and metastasis of gastric cancer ([@b39-etm-0-0-8726]). In addition, the present study further determined that EIF3B is associated with the histologic grade and survival status of patients with liver cancer. Therefore, in-depth studies using experimental and bioinformatics methods are required.

EIF3B has been indicated to have a marked influence on the prognosis of patients with cancer. In the present study, it was observed that upregulation of EIF3B was associated with poor overall/relapse-free survival of patients with liver cancer. In addition, patients with high EIF3B expression in clear cell renal cell carcinoma, esophageal squamous cell carcinoma and non-small cell lung cancer had a shorter survival time ([@b6-etm-0-0-8726],[@b7-etm-0-0-8726],[@b11-etm-0-0-8726]). In order to further explore the association between EIF3B and clinical characteristics of patients with liver cancer, a subgroup analysis was performed. As the TCGA-LIHC dataset does not have a Barcelona Clinic Liver Cancer staging system, TNM staging was used. Kaplan-Meier subgroup analysis indicated that high expression of EIF3B was associated with poor overall survival in the subgroups of females, younger (\<55) or older (≥55) patients, R0, G2, G3, stage I and stage III. Furthermore, high expression of EIF3B was associated with poor relapse-free survival in the subgroups of females, older patients, R0, G2 and stage III. However, Tian *et al* ([@b11-etm-0-0-8726]) reported that upregulation of EIF3B was associated with tumor depth, TNM stage and lymph node metastasis in patients with esophageal squamous cell carcinoma. However, the results of the present study indicated that EIF3B was related to histological grade and survival status. This may be linked to the heterogeneity of tumor types and individual differences, which may help to select personalized treatments. Owing to the TCGA-LIHC data not including the body mass index and the presence of diabetes mellitus as variables, it is not possible to calculate their association with the prognosis of patients.

In the GSEA analysis, high EIF3B expression was indicated to be associated with MYC-V1, MYC-V2 and DNA repair in liver cancer. The MYC oncogene is an important regulator of liver cancer progression. Previous studies have indicated that MYC is able to promote the proliferation, metastasis and metabolism of liver cancer by regulating signaling pathways including AKT/mTOR and RAS/mitogen-activated protein kinase ([@b40-etm-0-0-8726]). In addition, each replication of DNA in cancer cells may cause a large amount of damage, including DNA substitutions or deletions ([@b43-etm-0-0-8726]). Therefore, DNA repair mechanisms (damage induction, signal transduction, signal response) are particularly important. This may explain why EIF3B may promote the progression of liver cancer through MYC-V1/V2 and DNA repair pathways.

The present study mainly uncovered the prognostic value of the EIF3B mRNA expression in liver cancer. Along with other studies on EIF3B, the present study contributed to a better understanding of the role of EIF3B, as well as the great possibility for precise prognostication. However, the underlying mechanisms remain to be fully elucidated and require further exploration by scientific research. In the future, the mechanisms of EIF3B will be studied at a deeper level.

In conclusion, the present study investigated the prognostic value of EIF3B in patients with liver cancer. High EIF3B expression was proved to be a potential and independent prognostic biomarker for liver cancer. Future work will include *in vivo* and *in vitro* experiments to explore the biological functions of EIF3B and the underlying mechanisms.
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![Differences in EIF3B expression among subgroups of patients. Boxplots showing differences in EIF3B expression according to (A) tissue type (P\<0.001 vs. normal tissue controls), (B) age, (C) sex, (D) histologic grade (P\<0.001), (E) histological type, (F) T classification, (G) N classification, (H) M classification, (I) radiation therapy, (J) residual tumor classification, (K) sample type, (L) clinical stage and (M) vital status (P=0.005). EIF3B, eukaryotic translation initiation factor 3 subunit B. G1-4, grade relating to degree of differentiation; T1-4, size and or extension of the primary tumor; TX, tumor could not be assessed; N0, no regional lymph node metastasis; N1, regional lymph node metastasis present; NX, lymph nodes could not be assessed; M0, no distant metastasis; M1, metastasis to distant organs; MX, metastasis could not be assessed; R0, no residual tumor visible under the microscope; R1, residual tumor visible under the microscope; R2, residual tumor visible to the naked eye; RX, residual tumor could not be assessed.](etm-20-01-0436-g00){#f1-etm-0-0-8726}

![Receiver-operating characteristic curves for EIF3B in The Cancer Genome Atlas-liver hepatocellular carcinoma dataset. The ability of EIF3B to distinguish between the following was assessed: (A) Non-tumor vs. tumor sample; non-tumor sample vs. tumor sample of (B) stage I, (C) stage II, (D) stage III and (E) stage IV. AUC, area under the curve; EIF3B, eukaryotic translation initiation factor 3 subunit B.](etm-20-01-0436-g01){#f2-etm-0-0-8726}

![Kaplan-Meier analysis of the influence of EIF3B expression on overall survival. (A) All patients. Subgroup analysis for (B) females, (C) males, (D) younger patients (\<55), (E) older patients (≥55), (F) no lymph node dissection (R0), (G) lymph node dissection (R1/R2/RX), (H-M) histological grade, (H) G1/G2, (I) G3/G4, (J) G1, (K) G2, (L) G3, (M) G4, (N-Q) clinical stage (N) I, (O) II, (P) III, (Q) IV and (R) HCC. EIF3B, eukaryotic translation initiation factor 3 subunit B; HCC, hepatocellular carcinoma; G1-4, grade relating to degree of differentiation; T1-4, size and or extension of the primary tumor; TX, tumor could not be assessed; N0, no regional lymph node metastasis; N1, regional lymph node metastasis present; NX, lymph nodes could not be assessed; M0, no distant metastasis; M1, metastasis to distant organs; MX, metastasis could not be assessed; R0, no residual tumor visible under the microscope; R1, residual tumor visible under the microscope; R2, residual tumor visible to the naked eye; RX, residual tumor could not be assessed. The number of results censored (removed from surviving) is indicated below the survival curve.](etm-20-01-0436-g02){#f3-etm-0-0-8726}

![Kaplan-Meier analysis of the influence of EIF3B expression on relapse-free survival. (A) All patients. (B-R) Subgroup analysis for (B) females, (C) males, (D) younger patients (\<55), (E) older patients (≥55), (F) no lymph node dissection (R0), (G) lymph node dissection (R1/R2/RX), (H-K) histological grade (H) G1, (I) G2, (J) G3, (K) G4, (L-N) clinical stage (L) I, (M) II, (N) III and (O) HCC. EIF3B, eukaryotic translation initiation factor 3 subunit B; HCC, hepatocellular carcinoma; G1-4, grade relating to degree of differentiation; T1-4, size and or extension of the primary tumor; TX, tumor could not be assessed; N0, no regional lymph node metastasis; N1, regional lymph node metastasis present; NX, lymph nodes could not be assessed; M0, no distant metastasis; M1, metastasis to distant organs; MX, metastasis could not be assessed; R0, no residual tumor visible under the microscope; R1, residual tumor visible under the microscope; R2, residual tumor visible to the naked eye; RX, residual tumor could not be assessed. The number of results censored (removed from surviving) is indicated below the survival curve.](etm-20-01-0436-g03){#f4-etm-0-0-8726}

![Enrichment plots from GSEA. The GSEA results indicated that (A) the MYC-V1, (B) the MYC-V2 and (C) the DNA repair pathway are differentially enriched in high EIF3B expression and low EIF3B expression groups. GSEA, gene set enrichment analysis.](etm-20-01-0436-g04){#f5-etm-0-0-8726}

###### 

Demographic and clinical characteristics of the cohort from The Cancer Genome Atlas-liver hepatocellular carcinoma dataset.

  Characteristics                         N (373)
  --------------------------------------- -------------
  Age (years)                              
       \<55                               117 (31.45)
       ≥55                                255 (68.55)
       NA                                 1 (0.00)
  Sex                                      
       Female                             121 (32.44)
       Male                               252 (67.56)
  Histological type                        
       Fibrolamellar carcinoma            3 (0.80)
       Hepatocellular carcinoma           363 (97.32)
       Hepatocholangiocarcinoma (mixed)   7 (1.88)
  Histologic grade                         
       NA                                 5 (1.34)
       G1                                 55 (14.75)
       G2                                 178 (47.72)
       G3                                 123 (32.98)
       G4                                 12 (3.22)
  Stage                                    
       NA                                 24 (6.43)
       I                                  172 (46.11)
       II                                 87 (23.32)
       III                                85 (22.79)
       IV                                 5 (1.34)
  T classification                         
       NA                                 2 (0.54)
       T1                                 182 (48.79)
       T2                                 95 (25.47)
       T3                                 80 (21.45)
       T4                                 13 (3.49)
       TX                                 1 (0.27)
  N classification                         
       NA                                 1 (0.27)
       N0                                 253 (67.83)
       N1                                 4 (1.07)
       NX                                 115 (30.83)
  M classification                         
       M0                                 267 (71.58)
       M1                                 4 (1.07)
       MX                                 102 (27.35)
  Radiation therapy                        
       NA                                 25 (6.70)
       No                                 340 (91.15)
       Yes                                8 (2.14)
  Residual tumor                           
       NA                                 7 (1.88)
       R0                                 326 (87.40)
       R1                                 17 (4.56)
       R2                                 1 (0.27)
       RX                                 22 (5.90)
  Vital status                             
       Deceased                           130 (34.85)
       Alive                              243 (65.15)
  Sample type                              
       Primary tumor                      371 (99.46)
       Recurrent tumor                    2 (0.54)
  Overall survival (ten years)             
       No                                 237 (64.58)
       Yes                                130 (35.42)
  Relapse-free survival (ten years)        
       No                                 179 (55.94)
       Yes                                141 (44.06)
  EIF3B                                    
       High                               109 (29.22)
       Low                                264 (70.78)

NA, not available; EIF3B, eukaryotic translation initiation factor 3 subunit B; G1-4, grade relating to degree of differentiation; T1-4, size and or extension of the primary tumor; TX, tumor could not be assessed; N0, no regional lymph node metastasis; N1, regional lymph node metastasis present; NX, lymph nodes could not be assessed; M0, no distant metastasis; M1, metastasis to distant organs; MX, metastasis could not be assessed; R0, no residual tumor visible under the microscope; R1, residual tumor visible under the microscope; R2, residual tumor visible to the naked eye; RX, residual tumor could not be assessed.

###### 

Association between the expression of EIF3B and the clinicopathological characteristics of patients with liver cancer.

                                          EIF3B expression                                         
  --------------------------------------- ------------------ ------------- ------------- --------- ---------
  Age (years)                                                                            0.089     0.765
       \<55                               117                36 (33.03)    81 (30.80)               
       ≥55                                255                73 (66.97)    182 (69.20)              
  Sex                                                                                    0.484     0.486
       Female                             121                32 (29.36)    89 (33.71)               
       Male                               252                77 (70.64)    175 (66.29)              
  Histological type                                                                      1.251     0.534
       Fibrolamellar carcinoma            3                  0 (0.00)      3 (1.14)                 
       Hepatocellular carcinoma           363                107 (98.17)   256 (96.97)              
       Hepatocholangiocarcinoma (mixed)   7                  2 (1.83)      5 (1.89)                 
  Histologic grade                                                                       17.796    \<0.001
       G1                                 55                 9 (8.33)      46 (17.69)               
       G2                                 178                45 (41.67)    133 (51.15)              
       G3                                 123                46 (42.59)    77 (29.62)               
       G4                                 12                 8 (7.41)      4 (1.54)                 
  Stage                                                                                  4.532     0.209
       I                                  172                43 (40.95)    129 (52.87)              
       II                                 87                 32 (30.48)    55 (22.54)               
       III                                85                 28 (26.67)    57 (23.36)               
       IV                                 5                  2 (1.9)       3 (1.23)                 
  T classification                                                                       7.720     0.102
       T1                                 182                44 (40.37)    138 (52.67)              
       T2                                 95                 34 (31.19)    61 (23.28)               
       T3                                 80                 29 (26.61)    51 (19.47)               
       T4                                 13                 2 (1.83)      11 (4.2)                 
       TX                                 1                  0 (0.00)      1 (0.38)                 
  N classification                                                                       1.936     0.379
       N0                                 253                77 (70.64)    176 (66.92)              
       N1                                 4                  0 (0.00)      4 (1.52)                 
       NX                                 115                32 (29.36)    83 (31.56)               
  M classification                                                                       2.882     0.236
       M0                                 267                83 (76.15)    184 (69.70)              
       M1                                 4                  2 (1.83)      2 (0.76)                 
       MX                                 102                24 (22.02)    78 (29.55)               
  Radiation therapy                                                                      \<0.001   \>0.999
       No                                 340                92 (97.87)    248 (97.64)              
       Yes                                8                  2 (2.13)      6 (2.36)                 
  Residual tumor                                                                         5.116     0.163
       R0                                 326                98 (91.59)    228 (88.03)              
       R1                                 17                 5 (4.67)      12 (4.63)                
       R2                                 1                  1 (0.93)      0 (0.00)                 
       RX                                 22                 3 (2.80)      19 (7.34)                
  Vital status                                                                           17.505    \<0.001
       Deceased                           130                56 (51.38)    74 (28.03)               
       Alive                              243                53 (48.62)    190 (71.97)              
  Sample type                                                                            0.017     0.895
       Primary tumor                      371                109(100)      262 (99.24)              
       Recurrent tumor                    2                  0 (0.00)      2 (0.76)                 
  Overall survival (ten years)                                                           18.690    \<0.001
       No                                 237                50 (47.17)    187 (71.65)              
       Yes                                130                56 (52.83)    74 (28.35)               
  Relapse-free survival (ten years)                                                      1.018     0.312
       No                                 179                42 (50.6)     137 (57.81)              
       Yes                                141                41 (49.4)     100 (42.19)              

EIF3B, eukaryotic translation initiation factor 3 subunit B; G1-4, grade relating to degree of differentiation; T1-4, size and or extension of the primary tumor; TX, tumor could not be assessed; N0, no regional lymph node metastasis; N1, regional lymph node metastasis present; NX, lymph nodes could not be assessed; M0, no distant metastasis; M1, metastasis to distant organs; MX, metastasis could not be assessed; R0, no residual tumor visible under the microscope; R1, residual tumor visible under the microscope; R2, residual tumor visible to the naked eye; RX, residual tumor could not be assessed.

###### 

Summary of univariate and multivariate Cox regression analyses for overall survival duration (ten years).

                                                                                               Univariate analysis   Multivariate analysis                                
  -------------------------------------------------------------------------------------------- --------------------- ----------------------- --------- ------ ----------- ---------
  Age (≥55/\<55 years)                                                                         1.00                  0.69-1.45               0.997                         
  Sex (male/female)                                                                            0.80                  0.56-1.14               0.220                         
  Histological type (hepatocholangiocarcinoma/Hepatocellular, Hepatocellular /fibrolamellar)   0.99                  0.27-3.66               0.986                         
  Histologic grade (G4/G3/G2/G1)                                                               1.04                  0.84-1.30               0.698                         
  Stage (IV/III/II/I)                                                                          1.38                  1.15-1.66               0.001     0.81   0.65-1.01   0.060
  T classification (T4/T3/T2/T1/NX)                                                            1.66                  1.39-1.99               \<0.001   1.91   1.51-2.42   \<0.001
  N classification (N1/N0/NX)                                                                  0.73                  0.51-1.05               0.086                         
  M classification (M1/M0/MX)                                                                  0.72                  0.49-1.04               0.077                         
  Radiation therapy (yes/no)                                                                   0.51                  0.26-1.03               0.060                         
  Residual tumor classification (RX/R2/R1/R0)                                                  1.42                  1.13-1.80               0.003     1.45   1.13-1.87   0.004
  EIF3B (high/low)                                                                             2.41                  1.70-3.42               \<0.001   2.44   1.71-3.47   \<0.001

EIF3B, eukaryotic translation initiation factor 3 subunit B; G1-4, grade relating to degree of differentiation; T1-4, size and or extension of the primary tumor; TX, tumor could not be assessed; N0, no regional lymph node metastasis; N1, regional lymph node metastasis present; NX, lymph nodes could not be assessed; M0, no distant metastasis; M1, metastasis to distant organs; MX, metastasis could not be assessed; R0, no residual tumor visible under the microscope; R1, residual tumor visible under the microscope; R2, residual tumor visible to the naked eye; RX, residual tumor could not be assessed.

###### 

Summary of univariate and multivariate Cox regression analyses or relapse-free survival duration.

                                                                                               Univariate analysis   Multivariate analysis                                
  -------------------------------------------------------------------------------------------- --------------------- ----------------------- --------- ------ ----------- ---------
  Age (≥55/\<55 years)                                                                         0.90                  0.63-1.28               0.550                         
  Sex (male/female)                                                                            0.99                  0.70-1.41               0.966                         
  Histological type (hepatocholangiocarcinoma/hepatocellular, hepatocellular /fibrolamellar)   2.02                  0.66-6.24               0.220                         
  Histologic grade (G4/G3/G2/G1)                                                               0.98                  0.80-1.21               0.883                         
  Stage (IV/III/II/I)                                                                          1.66                  1.38-1.99               \<0.001   1.10   0.85-1.42   0.473
  T classification (T4/T3/T2/T1/TX)                                                            1.78                  1.49-2.12               \<0.001   1.67   1.28-2.18   \<0.001
  N classification (N1/N0/NX)                                                                  0.97                  0.67-1.40               0.874                         
  M classification (M1/M0/MX)                                                                  1.17                  0.79-1.74               0.432                         
  Radiation therapy (yes/no)                                                                   0.74                  0.26-2.16               0.584                         
  Residual tumor classification (RX/R2/R1/R0)                                                  1.28                  1.01-1.61               0.042     1.36   1.07-1.73   0.012
  EIF3B (high/low)                                                                             1.58                  1.10-2.28               0.014     1.54   1.06-2.23   0.022

EIF3B, eukaryotic translation initiation factor 3 subunit B; G1-4, grade relating to degree of differentiation; T1-4, size and/or extension of the primary tumor; TX, tumor could not be assessed; N0, no regional lymph node metastasis; N1, regional lymph node metastasis present; NX, lymph nodes could not be assessed; M0, no distant metastasis; M1, metastasis to distant organs; MX, metastasis could not be assessed; R0, no residual tumor visible under the microscope; R1, residual tumor visible under the microscope; R2, residual tumor visible to the naked eye; RX, residual tumor could not be assessed.

###### 

Gene sets enriched in phenotype high.

  Molecular signatures database collection   Gene set name             NES     NOM P-value   FDR q-value
  ------------------------------------------ ------------------------- ------- ------------- -------------
  h.all.v6.2.symbols.gmt                     HALLMARK_MYC_TARGETS_V2   2.154   0.004         0.006
  h.all.v6.2.symbols.gmt                     HALLMARK_MYC_TARGETS_V1   2.028   0.009         0.010
  h.all.v6.2.symbols.gmt                     HALLMARK_DNA_REPAIR       2.006   \<0.001       0.009

Gene sets with NOM P-value \<0.050 and FDR q-value \<0.250 were considered as significant. FDR, false discovery rate; NES, normalized enrichment score; NOM, nominal.

[^1]: ^\*^Contributed equally
